125 related articles for article (PubMed ID: 23470560)
1. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.
Diersch S; Wenzel P; Szameitat M; Eser P; Paul MC; Seidler B; Eser S; Messer M; Reichert M; Pagel P; Esposito I; Schmid RM; Saur D; Schneider G
Oncotarget; 2013 Feb; 4(2):277-88. PubMed ID: 23470560
[TBL] [Abstract][Full Text] [Related]
2. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
[TBL] [Abstract][Full Text] [Related]
3. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract][Full Text] [Related]
4. AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
Ingle K; LaComb JF; Graves LM; Baines AT; Bialkowska AB
PLoS One; 2023; 18(11):e0294065. PubMed ID: 37943821
[TBL] [Abstract][Full Text] [Related]
5. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
Babiker HM; Karass M; Recio-Boiles A; Chandana SR; McBride A; Mahadevan D
Expert Opin Investig Drugs; 2019 Jul; 28(7):583-592. PubMed ID: 31215251
[No Abstract] [Full Text] [Related]
6. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma.
Grbovic-Huezo O; Pitter KL; Lecomte N; Saglimbeni J; Askan G; Holm M; Melchor JP; Chandwani R; Joshi S; Haglund C; Iacobuzio-Donahue CA; Chiosis G; Tammela T; Leach SD
Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30670-30678. PubMed ID: 33199632
[TBL] [Abstract][Full Text] [Related]
7. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.
Mace TA; Shakya R; Elnaggar O; Wilson K; Komar HM; Yang J; Pitarresi JR; Young GS; Ostrowski MC; Ludwig T; Bekaii-Saab T; Bloomston M; Lesinski GB
Oncotarget; 2015 Dec; 6(42):44509-22. PubMed ID: 26575024
[TBL] [Abstract][Full Text] [Related]
8. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
Allen-Petersen BL; Risom T; Feng Z; Wang Z; Jenny ZP; Thoma MC; Pelz KR; Morton JP; Sansom OJ; Lopez CD; Sheppard B; Christensen DJ; Ohlmeyer M; Narla G; Sears RC
Cancer Res; 2019 Jan; 79(1):209-219. PubMed ID: 30389701
[TBL] [Abstract][Full Text] [Related]
9. HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B.
Malvi P; Chava S; Cai G; Hu K; Zhu LJ; Edwards YJK; Green MR; Gupta R; Wajapeyee N
Cell Rep Med; 2023 Nov; 4(11):101285. PubMed ID: 37951219
[TBL] [Abstract][Full Text] [Related]
10. AKT and mTOR expression in human pancreatic ductal adenocarcinoma. Relevance for tumor biology.
Handra-Luca A
Pathol Res Pract; 2023 Nov; 251():154878. PubMed ID: 37890271
[TBL] [Abstract][Full Text] [Related]
11. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.
Bulle A; Liu P; Seehra K; Bansod S; Chen Y; Zahra K; Somani V; Khawar IA; Chen HP; Dodhiawala PB; Li L; Geng Y; Mo CK; Mahsl J; Ding L; Govindan R; Davies S; Mudd J; Hawkins WG; Fields RC; DeNardo DG; Knoerzer D; Held JM; Grierson PM; Wang-Gillam A; Ruzinova MB; Lim KH
Nat Commun; 2024 Mar; 15(1):2503. PubMed ID: 38509064
[TBL] [Abstract][Full Text] [Related]
12. Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter gamma-aminobutyric acid.
Al-Wadei HA; Plummer HK; Schuller HM
Carcinogenesis; 2009 Mar; 30(3):506-11. PubMed ID: 19131543
[TBL] [Abstract][Full Text] [Related]
13. Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors.
Roy Chaudhuri T; Lin Q; Stachowiak EK; Rosario SR; Spernyak JA; Ma WW; Stachowiak MK; Greene MK; Quinn GP; McDade SS; Clynes M; Scott CJ; Straubinger RM
Clin Cancer Res; 2024 Apr; 30(7):1367-1381. PubMed ID: 38270582
[TBL] [Abstract][Full Text] [Related]
14. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.
Driscoll DR; Karim SA; Sano M; Gay DM; Jacob W; Yu J; Mizukami Y; Gopinathan A; Jodrell DI; Evans TR; Bardeesy N; Hall MN; Quattrochi BJ; Klimstra DS; Barry ST; Sansom OJ; Lewis BC; Morton JP
Cancer Res; 2016 Dec; 76(23):6911-6923. PubMed ID: 27758884
[TBL] [Abstract][Full Text] [Related]
15. Differential modulation of cellular phenotype and drug sensitivity by extracellular matrix proteins in primary and metastatic pancreatic cancer cells.
Usman OH; Kumar S; Walker RR; Xie G; Sumajit HC; Jalil AR; Ramakrishnan S; Dooling LJ; Wang YJ; Irianto J
Mol Biol Cell; 2023 Dec; 34(13):ar130. PubMed ID: 37903222
[TBL] [Abstract][Full Text] [Related]
16. Minocycline and photodynamic priming significantly improve chemotherapy efficacy in heterotypic spheroids of pancreatic ductal adenocarcinoma.
Bano S; Alburquerque JQ; Roberts HJ; Pang S; Huang HC; Hasan T
J Photochem Photobiol B; 2024 Jun; 255():112910. PubMed ID: 38663337
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic developments in pancreatic cancer.
Hu ZI; O'Reilly EM
Nat Rev Gastroenterol Hepatol; 2024 Jan; 21(1):7-24. PubMed ID: 37798442
[TBL] [Abstract][Full Text] [Related]
18. The protein phosphatase-2A subunit PR130 is involved in the formation of cytotoxic protein aggregates in pancreatic ductal adenocarcinoma cells.
Nguyen A; Mustafa AM; Leydecker AK; Halilovic M; Murr J; Butter F; Krämer OH
Cell Commun Signal; 2024 Apr; 22(1):217. PubMed ID: 38570831
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer.
Jiménez DJ; Javed A; Rubio-Tomás T; Seye-Loum N; Barceló C
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474109
[TBL] [Abstract][Full Text] [Related]
20. Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer.
Cheng C; Hu J; Mannan R; Bhattacharyya R; Rossiter NJ; Magnuson B; Wisniewski JP; Zheng Y; Xiao L; Li C; Awad D; He T; Bao Y; Zhang Y; Cao X; Wang Z; Mehra R; Morlacchi P; Sahai V; di Magliano MP; Shah YM; Ding K; Qiao Y; Lyssiotis CA; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38562800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
